Topiramate Augmentation in Bulimia Nervosa Partial Responders
This study has been withdrawn prior to enrollment.
(Difficulty with enrollment.)
Sponsor:
Neuropsychiatric Research Institute, Fargo, North Dakota
Information provided by:
Neuropsychiatric Research Institute, Fargo, North Dakota
ClinicalTrials.gov Identifier:
NCT00988481
First received: October 1, 2009
Last updated: June 29, 2010
Last verified: June 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The goal of this study is to generate pilot data exploring the addition of an augmentation (additional) medication to patients suffering from bulimia nervosa who have responded but not had complete symptom resolution with a course of standard medication treatment.
| Condition | Intervention | Phase |
|---|---|---|
|
Bulimia Nervosa |
Drug: Topiramate |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Topiramate Augmentation in Bulimia Nervosa Partial Responders |
Resource links provided by NLM:
Further study details as provided by Neuropsychiatric Research Institute, Fargo, North Dakota:
Primary Outcome Measures:
- Weekly number of binge eating episodes and purging episodes [ Time Frame: Weekly for 10 weeks ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Abstinence from BN symptoms [ Time Frame: Baseline and endpoint (week 1 and week 10) ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 10 |
| Study Start Date: | September 2009 |
| Estimated Study Completion Date: | September 2010 |
| Estimated Primary Completion Date: | August 2010 (Final data collection date for primary outcome measure) |
Intervention Details:
Detailed Description:
-
Drug: Topiramate
Topiramate titrated to 200mg/day over four weeks, for ten weeks
Other Name: Topamax
The aim of this study is to determine whether the addition of an augmentation medication (topiramate 200mg/d) will confer additional reductions in symptomatology in BN patients who have received six weeks of standard pharmacological treatment with fluoxetine 60 mg/day or its equivalent and had a partial response but are not in symptomatic remission.
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male or female subjects meeting DSM-IV diagnostic criteria for BN.
- Subjects must be between the ages of 18 and 60 years.
- Subjects must currently demonstrate partial response to a standard BN pharmacotherapy treatment.
- Women of child-bearing potential must be practicing an accepted method of birth control (barrier method or oral contraceptive) and have a negative pregnancy test at baseline.
- Subjects must be of good general health by history, laboratory assessment and physical exam.
- Subject's BMI must be >20 and <27 kg/m^2.
Exclusion Criteria:
- Subjects who are allergic to topiramate.
- Subjects who meet DSM-IV criteria for anorexia nervosa.
- Women who are pregnant or nursing at the time of study.
- Subjects experiencing clinically significant, unstable neurological, cardiac, hepatic or renal disease or narrow angle glaucoma.
- Subjects with a history of nephrolithiasis.
- Subjects with a serum potassium <3.0 mmol/L
- Subjects cannot start psychotherapy during the study.
- Subjects currently or with a past history of meeting DSM-IV diagnostic criteria for schizophrenia, schizoaffective disorder, or bipolar disorder.
- Subjects receiving antipsychotic agents, mood stabilizers, antianxiety agents or other non-antidepressant psychotropic agent currently.
- Subjects currently or with a history within the past year of meeting DSM-IV diagnostic criteria for substance abuse.
- Subjects who are experiencing clinically significant suicidal ideation (subjects will be referred to appropriate caregiver).
- Subjects who have participated in an investigational drug study in the past 30 days.
- Subjects who are receiving any prescription medications other than oral contraceptives that will interact with any of the study medication.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00988481
Locations
| United States, North Dakota | |
| Neuropsychiatric Research Institute | |
| Fargo, North Dakota, United States, 58103 | |
Sponsors and Collaborators
Neuropsychiatric Research Institute, Fargo, North Dakota
Investigators
| Principal Investigator: | James L Roerig, PharmD, BCPP | Neuropsychiatric Research Institute, University of North Dakota |
More Information
Additional Information:
No publications provided
| Responsible Party: | James L. Roerig, PharmD, BCPP, Neuropsychiatric Research Institute |
| ClinicalTrials.gov Identifier: | NCT00988481 History of Changes |
| Other Study ID Numbers: | 200909-046 |
| Study First Received: | October 1, 2009 |
| Last Updated: | June 29, 2010 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Neuropsychiatric Research Institute, Fargo, North Dakota:
|
Bulimia Nervosa Topiramate Augmentation |
Additional relevant MeSH terms:
|
Bulimia Bulimia Nervosa Hyperphagia Signs and Symptoms, Digestive Signs and Symptoms Eating Disorders Mental Disorders Topiramate |
Anticonvulsants Central Nervous System Agents Therapeutic Uses Pharmacologic Actions Neuroprotective Agents Protective Agents Physiological Effects of Drugs Anti-Obesity Agents |
ClinicalTrials.gov processed this record on May 16, 2013